An open-label, randomized, post-authorization study of mirabegron in Chinese participants with overactive bladder
Objective: To assess efficacy and safety of mirabegron 25 mg/day and 50 mg/day for overactive bladder in Chinese participants. Methods: Participants of ≥18 years with overactive bladder symptoms lasting for ≥12 weeks, a mean of ≥8 micturitions per 24 h, and a mean of at least one episode of Grade 3...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Asian Journal of Urology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2214388224000936 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832582141807951872 |
|---|---|
| author | Zhipeng Zhang Deyi Luo Zhong Chen Peng Zhang Ganping Zhong Keji Xie Zhuoqun Xu Xudong Li Jianye Wang Yingfan Yang Farid Abdul Hadi Arianne Schild |
| author_facet | Zhipeng Zhang Deyi Luo Zhong Chen Peng Zhang Ganping Zhong Keji Xie Zhuoqun Xu Xudong Li Jianye Wang Yingfan Yang Farid Abdul Hadi Arianne Schild |
| author_sort | Zhipeng Zhang |
| collection | DOAJ |
| description | Objective: To assess efficacy and safety of mirabegron 25 mg/day and 50 mg/day for overactive bladder in Chinese participants. Methods: Participants of ≥18 years with overactive bladder symptoms lasting for ≥12 weeks, a mean of ≥8 micturitions per 24 h, and a mean of at least one episode of Grade 3 or 4 urgency or urge incontinence per 24 h based on the Patient Perception of Intensity of Urgency Scale over a 3-day micturition diary period were randomized 2:1 to open-label treatment with oral mirabegron 50 mg or 25 mg once daily for 12 weeks (15 sites in China, January 2021–March 2022). A dose escalation from 25 mg/day to 50 mg/day was permitted at weeks 4 and 8 according to the investigators' discretion. The primary efficacy endpoint was the change from baseline to Week 12 in the mean number of micturitions per 24 h in those randomized to mirabegron 50 mg/day. Secondary efficacy endpoints were the change in mean number of micturitions at weeks 4 and 8 in the mirabegron 50 mg/day group and weeks 4, 8, and 12 in the mirabegron 25 mg/day group, change from baseline to weeks 4, 8, and 12 in Grade 3 or 4 urgency episodes on the Patient Perception of Intensity of Urgency Scale, episodes of daytime incontinence, nighttime incontinence, and urgency incontinence, and Overactive Bladder Symptom Score for mirabegron 50 mg/day and 25 mg/day groups. Results: Statistically significant reduction (p<0.001) from baseline to Week 12 was observed in mean micturitions per 24 h for participants randomized to mirabegron 50 mg/day: mean±standard error: 11.71±0.43 at baseline, 7.80±0.24 at Week 12; adjusted mean change: −3.73 (95% confidence interval −4.30 to −3.16). Both doses showed statistically significant improvement in secondary efficacy endpoints at weeks 4, 8, and 12 versus baseline. Safety was consistent with mirabegron's known safety profile. Conclusion: The results support a mirabegron dosage of 50 mg/day for the treatment of OAB in China. |
| format | Article |
| id | doaj-art-0b35f3694fda49aba6ca3708580c87e8 |
| institution | Kabale University |
| issn | 2214-3882 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Asian Journal of Urology |
| spelling | doaj-art-0b35f3694fda49aba6ca3708580c87e82025-01-30T05:14:16ZengElsevierAsian Journal of Urology2214-38822025-01-011217986An open-label, randomized, post-authorization study of mirabegron in Chinese participants with overactive bladderZhipeng Zhang0Deyi Luo1Zhong Chen2Peng Zhang3Ganping Zhong4Keji Xie5Zhuoqun Xu6Xudong Li7Jianye Wang8Yingfan Yang9Farid Abdul Hadi10Arianne Schild11Department of Urology, Beijing Hospital, National Center of Gerontology and Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, ChinaDepartment of Urology, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, ChinaDepartment of Urology, Lanzhou University Second Hospital, Lanzhou, ChinaDepartment of Urology, Guangzhou First People's Hospital, Guangzhou, ChinaDepartment of Urology, Wuxi People's Hospital, Wuxi, ChinaDepartment of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, ChinaDepartment of Urology, Beijing Hospital, National Center of Gerontology and Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, ChinaMedical Affairs, Astellas Pharma (China), Inc., Shenyang, ChinaMedical Affairs, Astellas Pharma Singapore Pte. Ltd., Singapore; Corresponding author.Analytics & Data Science, Astellas Pharma Global Development, Inc., Northbrook, IL, USAObjective: To assess efficacy and safety of mirabegron 25 mg/day and 50 mg/day for overactive bladder in Chinese participants. Methods: Participants of ≥18 years with overactive bladder symptoms lasting for ≥12 weeks, a mean of ≥8 micturitions per 24 h, and a mean of at least one episode of Grade 3 or 4 urgency or urge incontinence per 24 h based on the Patient Perception of Intensity of Urgency Scale over a 3-day micturition diary period were randomized 2:1 to open-label treatment with oral mirabegron 50 mg or 25 mg once daily for 12 weeks (15 sites in China, January 2021–March 2022). A dose escalation from 25 mg/day to 50 mg/day was permitted at weeks 4 and 8 according to the investigators' discretion. The primary efficacy endpoint was the change from baseline to Week 12 in the mean number of micturitions per 24 h in those randomized to mirabegron 50 mg/day. Secondary efficacy endpoints were the change in mean number of micturitions at weeks 4 and 8 in the mirabegron 50 mg/day group and weeks 4, 8, and 12 in the mirabegron 25 mg/day group, change from baseline to weeks 4, 8, and 12 in Grade 3 or 4 urgency episodes on the Patient Perception of Intensity of Urgency Scale, episodes of daytime incontinence, nighttime incontinence, and urgency incontinence, and Overactive Bladder Symptom Score for mirabegron 50 mg/day and 25 mg/day groups. Results: Statistically significant reduction (p<0.001) from baseline to Week 12 was observed in mean micturitions per 24 h for participants randomized to mirabegron 50 mg/day: mean±standard error: 11.71±0.43 at baseline, 7.80±0.24 at Week 12; adjusted mean change: −3.73 (95% confidence interval −4.30 to −3.16). Both doses showed statistically significant improvement in secondary efficacy endpoints at weeks 4, 8, and 12 versus baseline. Safety was consistent with mirabegron's known safety profile. Conclusion: The results support a mirabegron dosage of 50 mg/day for the treatment of OAB in China.http://www.sciencedirect.com/science/article/pii/S2214388224000936β3-adrenoceptor agonistChinese populationMicturitionMirabegronOveractive bladder |
| spellingShingle | Zhipeng Zhang Deyi Luo Zhong Chen Peng Zhang Ganping Zhong Keji Xie Zhuoqun Xu Xudong Li Jianye Wang Yingfan Yang Farid Abdul Hadi Arianne Schild An open-label, randomized, post-authorization study of mirabegron in Chinese participants with overactive bladder Asian Journal of Urology β3-adrenoceptor agonist Chinese population Micturition Mirabegron Overactive bladder |
| title | An open-label, randomized, post-authorization study of mirabegron in Chinese participants with overactive bladder |
| title_full | An open-label, randomized, post-authorization study of mirabegron in Chinese participants with overactive bladder |
| title_fullStr | An open-label, randomized, post-authorization study of mirabegron in Chinese participants with overactive bladder |
| title_full_unstemmed | An open-label, randomized, post-authorization study of mirabegron in Chinese participants with overactive bladder |
| title_short | An open-label, randomized, post-authorization study of mirabegron in Chinese participants with overactive bladder |
| title_sort | open label randomized post authorization study of mirabegron in chinese participants with overactive bladder |
| topic | β3-adrenoceptor agonist Chinese population Micturition Mirabegron Overactive bladder |
| url | http://www.sciencedirect.com/science/article/pii/S2214388224000936 |
| work_keys_str_mv | AT zhipengzhang anopenlabelrandomizedpostauthorizationstudyofmirabegroninchineseparticipantswithoveractivebladder AT deyiluo anopenlabelrandomizedpostauthorizationstudyofmirabegroninchineseparticipantswithoveractivebladder AT zhongchen anopenlabelrandomizedpostauthorizationstudyofmirabegroninchineseparticipantswithoveractivebladder AT pengzhang anopenlabelrandomizedpostauthorizationstudyofmirabegroninchineseparticipantswithoveractivebladder AT ganpingzhong anopenlabelrandomizedpostauthorizationstudyofmirabegroninchineseparticipantswithoveractivebladder AT kejixie anopenlabelrandomizedpostauthorizationstudyofmirabegroninchineseparticipantswithoveractivebladder AT zhuoqunxu anopenlabelrandomizedpostauthorizationstudyofmirabegroninchineseparticipantswithoveractivebladder AT xudongli anopenlabelrandomizedpostauthorizationstudyofmirabegroninchineseparticipantswithoveractivebladder AT jianyewang anopenlabelrandomizedpostauthorizationstudyofmirabegroninchineseparticipantswithoveractivebladder AT yingfanyang anopenlabelrandomizedpostauthorizationstudyofmirabegroninchineseparticipantswithoveractivebladder AT faridabdulhadi anopenlabelrandomizedpostauthorizationstudyofmirabegroninchineseparticipantswithoveractivebladder AT arianneschild anopenlabelrandomizedpostauthorizationstudyofmirabegroninchineseparticipantswithoveractivebladder AT zhipengzhang openlabelrandomizedpostauthorizationstudyofmirabegroninchineseparticipantswithoveractivebladder AT deyiluo openlabelrandomizedpostauthorizationstudyofmirabegroninchineseparticipantswithoveractivebladder AT zhongchen openlabelrandomizedpostauthorizationstudyofmirabegroninchineseparticipantswithoveractivebladder AT pengzhang openlabelrandomizedpostauthorizationstudyofmirabegroninchineseparticipantswithoveractivebladder AT ganpingzhong openlabelrandomizedpostauthorizationstudyofmirabegroninchineseparticipantswithoveractivebladder AT kejixie openlabelrandomizedpostauthorizationstudyofmirabegroninchineseparticipantswithoveractivebladder AT zhuoqunxu openlabelrandomizedpostauthorizationstudyofmirabegroninchineseparticipantswithoveractivebladder AT xudongli openlabelrandomizedpostauthorizationstudyofmirabegroninchineseparticipantswithoveractivebladder AT jianyewang openlabelrandomizedpostauthorizationstudyofmirabegroninchineseparticipantswithoveractivebladder AT yingfanyang openlabelrandomizedpostauthorizationstudyofmirabegroninchineseparticipantswithoveractivebladder AT faridabdulhadi openlabelrandomizedpostauthorizationstudyofmirabegroninchineseparticipantswithoveractivebladder AT arianneschild openlabelrandomizedpostauthorizationstudyofmirabegroninchineseparticipantswithoveractivebladder |